Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation

Clin Genitourin Cancer. 2017 Feb;15(1):e69-e71. doi: 10.1016/j.clgc.2016.09.001. Epub 2016 Sep 17.

Authors

Allie E Steinberger¹, Patrick Cotogno¹, Elisa M Ledet¹, Brian Lewis¹, Oliver Sartor²

Affiliations

¹ Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA.
² Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA; Department of Medicine and Urology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA. Electronic address: [email protected].

PMID: 27726949
DOI: 10.1016/j.clgc.2016.09.001

No abstract available

Keywords: BRCA2; Mutation; Prostate cancer; Radium-223; mCRPC.

Publication types

Case Reports

MeSH terms

BRCA2 Protein / genetics*
Bone Neoplasms / drug therapy*
Bone Neoplasms / genetics
Bone Neoplasms / secondary
Humans
Male
Middle Aged
Mutation
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / genetics
Radiopharmaceuticals / administration & dosage*
Radiopharmaceuticals / therapeutic use
Radium / administration & dosage*
Radium / therapeutic use
Treatment Outcome

Substances

BRCA2 Protein
BRCA2 protein, human
Radiopharmaceuticals
Radium-223
Radium